Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects
April 20, 2022 07:00 ET
|
Trevena Inc.
OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Data replicate observations previously seen in a...
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund
April 18, 2022 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting
April 13, 2022 16:05 ET
|
Trevena Inc.
CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
March 31, 2022 07:02 ET
|
Trevena Inc.
CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Fourth Quarter and Full Year 2021 Results
March 31, 2022 07:00 ET
|
Trevena Inc.
-- OLINVYK® utilization gaining traction in key target markets Seasoned Biopharma Leader Patricia Drake appointed new Chief Commercial Officer Topline data of OLINVYK vs IV morphine in high-risk...
Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
March 30, 2022 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Present at the 2022 BIO CEO & Investor Conference
February 03, 2022 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical
January 27, 2022 09:00 ET
|
Trevena Inc.
Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success payments upon...
Trevena to Participate in the Upcoming January Conferences
January 03, 2022 16:05 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
December 13, 2021 07:00 ET
|
Trevena Inc.
3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start in early Q1 2022 CHESTERBROOK,...